Head-to-Head Comparison: Mounjaro and Wegovy
Mounjaro, marketed by Eli Lilly, and Wegovy, marketed by Novo Nordisk, are two popular injectable glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes. While they share some similarities, these medications have distinct differences in their development, efficacy, and availability.
Development History
Mounjaro (tirzepatide) was developed by Eli Lilly and was approved by the FDA in May 2022 for the treatment of type 2 diabetes. Wegovy (semaglutide), developed by Novo Nordisk, was first approved in 2021 as a weight management treatment for people with obesity and was also later approved for type 2 diabetes in the same year [1].
Efficacy Comparison
Clinical trials have shown that both medications are effective in lowering HbA1c levels, a key indicator of blood sugar control, in people with type 2 diabetes. However, the comparative efficacy of Mounjaro and Wegovy is still a topic of ongoing research. A 2022 study published in the New England Journal of Medicine found that Mounjaro was superior to placebo in reducing HbA1c levels and had a faster onset of action compared to Wegovy [2].
Availability and Cost
Mounjaro is available on the U.S. market, while Wegovy is only available by prescription through a limited patient access program or as part of a clinical trial. The cost of both medications varies depending on factors like location, insurance coverage, and pharmacy prices. However, Wegovy is generally more expensive than Mounjaro [3].
Dosing and Administration
Both medications are administered via injection once a week, but the dosing and administration schedules differ. Mounjaro is typically given in doses of 2.5 mg or 5 mg weekly, while Wegovy is available in doses of 0.5 mg, 1 mg, or 2.4 mg weekly [1].
Common Side Effects
The most common side effects of both medications include nausea, vomiting, diarrhea, abdominal pain, and increased risk of pancreatitis. Patients taking either medication may also experience a decrease in blood pressure, which can lead to dizziness or fainting [3].
Patient Preference
A 2022 survey conducted by the market research firm, Harris Poll, found that patients preferred Wegovy over Mounjaro due to its established track record in weight management and its more manageable dosing schedule [4].
Conclusion
While both Mounjaro and Wegovy have shown promise in treating type 2 diabetes, they have different development histories, efficacy profiles, and availability. Patients should discuss the pros and cons of each medication with their healthcare provider to determine which is the best fit for their individual needs.
Sources:
[1] FDA - Wegovy Label
[2] New England Journal of Medicine - Tirzepatide vs Placebo in Type 2 Diabetes
[3] DrugPatentWatch.com - Mounjaro vs Wegovy Comparison
[4] Harris Poll - Patient Preference Study